Sarepta therapeutics announces pipeline progress for multiple limb-girdle muscular dystrophy programs

Cambridge, mass.--(business wire)--sarepta therapeutics, inc. (nasdaq:srpt), the leader in precision genetic medicine for rare diseases, today shared updates from its clinical programs focused on limb-girdle muscular dystrophy (lgmd) subtypes 2c/r5, 2d/r3, and 2e/r4. srp-9005 for lgmd type 2c/r5: following input from the u.s. food and drug administration (fda), office of therapeutic products (otp), sarepta is cleared to proceed with dosing in study srp-9005-101 (compass) in the u.s. compass is.
SRPT Ratings Summary
SRPT Quant Ranking